NCT01364987CompletedPhase 1
A Phase 1, Open Label, Single Sequence, Drug Interaction Study of the Pharmacokinetics of ASP015K and Mycophenolate Mofetil (MMF) After Separate and Concomitant Administration to Healthy Adult Volunteers
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Astellas Pharma Inc
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Assessment of pharmacokinetic variables through analysis of blood and urine samples
Study Overview
Brief Summary
This study characterizes the pharmacokinetic effect of ASP015K on mycophenolate mofetil in healthy volunteers.
Detailed Description
The subjects will be confined to the unit for 13 days and have a brief follow-up visit to obtain hematology blood samples. Numerous blood and urine samples will be taken to determine the pharmacokinetics of the drugs.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •If female, the subject is at least 2 years post menopausal or is surgically sterile per documentation provided by a third party medical professional and the subject is not pregnant as documented by a negative serum pregnancy test
- •If male, the subject agrees to sexual abstinence and/or to use a highly effective method of birth control during the study period
- •Subject is medically healthy, with no clinically significant medical history or abnormalities
- •Subjects must weigh at least 45 kg and have a body mass index (BMI) of 18-32 kg/m2
Exclusion Criteria
- •Subject has a history of chronic diarrhea
- •Subject has been vaccinated within the last 60 days prior to study drug administration
- •The subject has a previous history of any clinically significant neurological, gastro-intestinal, renal, hepatic, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, and hematological disorder or disease
- •Subject has a positive test for hepatitis C antibody, or positive for hepatitis B surface antigen (HBsAg)
- •Subject has a history of the human immunodeficiency virus (HIV) antibody
- •The subject has an absolute neutrophil count (ANC) < 2500 cells/mm3
- •Subject has had clinically significant illness within 1 month prior to study drug administration
- •Subject has a recent history (within the last 6 months) of drug or alcohol abuse or a positive urine screen for alcohol or drugs of abuse/illegal drugs
Arms & Interventions
ASP015K and Mycophenolate Mofetil
Experimental
Intervention: ASP015K (Drug)
ASP015K and Mycophenolate Mofetil
Experimental
Intervention: Mycophenolate Mofetil (Drug)
Outcomes
Primary Outcomes
Assessment of pharmacokinetic variables through analysis of blood and urine samples
Time Frame: Up to 13 Days
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
Pharmacokinetics of Mmf and ValganciclovirKidney Transplant RecipientHeart Transplant RecipientNCT00189150University of Michigan16
Completed
Phase 1
A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and MetforminHealthy SubjectsNCT02760342Astellas Pharma Inc24
Completed
Phase 3
A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant RecipientsLung TransplantationNCT01014442Hoffmann-La Roche68
Completed
Phase 1
A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT01754805Astellas Pharma Inc15
Completed
Not Applicable
Pharmacokinetic Study of mycophenolate mofetil combined with rituximab in patients with Childhood-onset Complicated Frequently Relapsing or Steroid-dependent Nephrotic SyndromeChildhood-onset Complicated Frequently Relapsing or Steroid-dependent Nephrotic SyndromeJPRN-UMIN000016764Japanese Study Group of Kidney Disease in Children79